1
|
Bulhões E, Antunes VLJ, Mazetto R, Defante MLR, Garcia AC, Guida C. Catheter ablation versus medical therapy for atrial fibrillation in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis. Heart Rhythm 2024; 21:1595-1603. [PMID: 38621498 DOI: 10.1016/j.hrthm.2024.04.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Revised: 04/09/2024] [Accepted: 04/10/2024] [Indexed: 04/17/2024]
Abstract
BACKGROUND The benefit of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF) remains uncertain. OBJECTIVE We performed a systematic review and meta-analysis to compare catheter ablation and medical therapy (antiarrhythmics for rhythm or rate control) in patients with AF and HFpEF. METHODS We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials. Outcomes were the composite end points of death or heart failure (HF) hospitalization, all-cause death, cardiovascular death, all-cause rehospitalization, and HF hospitalization. Statistical analysis was performed using R statistical software, version 4.3.2 (R Foundation for Statistical Computing). Heterogeneity was assessed with I2 statistics. RESULTS We included 20,257 patients from 8 studies. Of those, 3 were derived from RCTs, either through post hoc analysis or subgroup analysis, and 5 were observational studies. The median follow-up ranged from 24.6 to 61.2 months. Compared with medical therapy, catheter ablation was associated with a statistically significant lower risk of death or HF hospitalization (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.47-0.83; P = .001; I2 = 66%), all-cause death (HR 0.68; 95% CI 0.46-0.99; P = .047; I2 = 61%), cardiovascular death (HR 0.42; 95% CI 0.21-0.84; P = .014; I2 = 22%), and HF hospitalization (HR 0.43; 95% CI 0.23-0.82; P = .011; I2 = 87%). CONCLUSION In this meta-analysis, catheter ablation was associated with a lower risk of all-cause death, cardiovascular death, HF hospitalization, and all-cause rehospitalization in comparison to medical therapy in patients with AF and HFpEF.
Collapse
Affiliation(s)
- Elísio Bulhões
- College of Higher Education of the United Amazon, Medicine Department, Redenção, Pará, Brazil
| | - Vanio L J Antunes
- Federal University of Health Sciences of Porto Alegre, Medicine Department, Porto Alegre, Rio Grande do Sul, Brazil
| | - Roberto Mazetto
- Amazonas State University, Medicine Department, Manaus, Amazonas, Brazil
| | - Maria L R Defante
- Redentor University Center, Medicine Department, Itaperuna, Rio de Janeiro, Brazil
| | - Anselmo C Garcia
- Goiás Military Police Hospital, Division of Cardiology, Goiânia, Goiás, Brazil
| | - Camila Guida
- Dante Pazzanese Institute of Cardiology, Division of Cardiology, São Paulo, São Paulo, Brazil.
| |
Collapse
|
2
|
Xie Z, Qi B, Wang Z, Li F, Chen C, Li C, Yuan S, Yao S, Zhou J, Ge J. Ablation for atrial fibrillation improves the outcomes in patients with heart failure with preserved ejection fraction. Europace 2023; 26:euad363. [PMID: 38099508 PMCID: PMC10754157 DOI: 10.1093/europace/euad363] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 12/08/2023] [Indexed: 12/29/2023] Open
Abstract
AIMS Patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have worse clinical outcomes than those with sinus rhythm (SR). We aim to investigate whether maintaining SR in patients with HFpEF through a strategy such as AF ablation would improve outcomes. METHODS AND RESULTS This is a cohort study that analysed 1034 patients (median age 69 [63-76] years, 46.2% [478/1034] female) with HFpEF and AF. Of these, 392 patients who underwent first-time AF ablation were assigned to the ablation group, and the remaining 642 patients, who received only medical therapy, were assigned to the no ablation group. The primary endpoint was a composite of all-cause death or rehospitalization for worsening heart failure. After a median follow-up of 39 months, the cumulative incidence of the primary endpoint was significantly lower in the ablation group compared to the no ablation group (adjusted hazard ratio [HR], 0.55 [95% CI, 0.37-0.82], P = 0.003) in the propensity score-matched model. Secondary endpoint analysis showed that the benefit of AF ablation was mainly driven by a reduction in rehospitalization for worsening heart failure (adjusted HR, 0.52 [95% CI, 0.34-0.80], P = 0.003). Patients in the ablation group showed a 33% relative decrease in atrial tachycardia/AF recurrence compared to the no ablation group (adjusted HR, 0.67 [95% CI, 0.54-0.84], P < 0.001). CONCLUSION Among patients with HFpEF and AF, the strategy of AF ablation to maintain SR was associated with a lower risk of the composite outcome of all-cause death or rehospitalization for worsening heart failure.
Collapse
Affiliation(s)
- Zhonglei Xie
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
| | - Baozhen Qi
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
| | - Zimu Wang
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
| | - Fuhai Li
- Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Chaofeng Chen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
| | - Chaofu Li
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
| | - Shuai Yuan
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
| | - Shun Yao
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
| | - Jingmin Zhou
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
| | - Junbo Ge
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Fenglin Road 180, Xuhui District, 200032 Shanghai, China
- Institutes of Biomedical Sciences, Fudan University, Yixueyuan Road 138, Xuhui District, 200032 Shanghai, China
| |
Collapse
|
3
|
Kemi Y, Yamashita E, Fujiwara T, Kario K, Sasaki T, Minami K, Miki Y, Goto K, Take Y, Nakamura K, Naito S. The prevalence and characteristics of candidates for percutaneous left atrial appendage occlusion using a WATCHMAN device among patients who underwent atrial fibrillation ablation in a Japanese population. J Echocardiogr 2021; 19:243-249. [PMID: 34296416 DOI: 10.1007/s12574-021-00538-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 06/22/2021] [Accepted: 07/14/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Percutaneous left atrial appendage occlusion (LAAO) using a WATCHMAN device could be a treatment option for patients with non-valvular atrial fibrillation (AF) with thromboembolic and bleeding risk. We sought to determine the prevalence and characteristics of patients with AF ablation who are potential candidates for WATCHMAN implantation in a Japanese population. METHODS We enrolled 2443 consecutive patients who had previously undergone AF ablation and transesophageal echocardiography (TEE). We assessed their clinical characteristics and measured their LAA orifice diameter and depth retrospectively using the obtained TEE images. We defined patients who met both anatomical criteria (LAA orifice max diameter: 17-31 mm and LAA max depth > LAA orifice max diameter) and clinical criteria (CHA2DS2-VASc score ≥ 2 and HAS-BLED score ≥ 3) as LAAO candidates. RESULTS Among the 2443 enrolled patients, 361 (15%) met the clinical criteria, and 1928 (79%) met the anatomical criteria. Thus 12% (293/2443) of the total patient group met the criteria of LAAO candidates. LAAO candidates showed larger left atrial (LA) volume (77.6 ± 30.1 vs. 67.7 ± 29.1 mL, P < 0.001), larger LAA orifice diameter (22.5 ± 3.2 vs. 22.0 ± 4.3 mm, P = 0.026), and larger LAA depth (28.9 ± 4.6 vs. 27.0 ± 4.8 mm, P < 0.001). LAAO candidates made up only 23% of patients with CHA2DS2-VASc score ≥ 2 (N = 1295), whereas 78% of patients with a HAS-BLED score ≥ 3 (N = 378) were LAAO candidates. CONCLUSION Twelve percent of patients who underwent AF ablation were potential candidates for LAAO using a WATCHMAN device in this Japanese population. It is imperative to evaluate bleeding risk when considering the indications for LAAO.
Collapse
Affiliation(s)
- Yuta Kemi
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan. .,Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
| | - Eiji Yamashita
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan.,Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan
| | - Takeshi Fujiwara
- Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan
| | - Kazuomi Kario
- Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan
| | - Takehito Sasaki
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan
| | - Kentaro Minami
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan
| | - Yuko Miki
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan
| | - Koji Goto
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan
| | - Yutaka Take
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan
| | - Kohki Nakamura
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan
| | - Shigeto Naito
- Gunma Prefectural Cardiovascular Center, 3-12 Kameizumi, Maebashi, Gunma, 371-0004, Japan
| |
Collapse
|
4
|
Sugumar H, Nanayakkara S, Vizi D, Wright L, Chieng D, Leet A, Mariani JA, Voskoboinik A, Prabhu S, Taylor AJ, Kalman JM, Kistler PM, Kaye DM, Ling LH. A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF. Eur J Heart Fail 2021; 23:785-796. [PMID: 33565197 DOI: 10.1002/ejhf.2122] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 02/03/2021] [Accepted: 02/03/2021] [Indexed: 12/28/2022] Open
Abstract
AIMS The impact of atrial fibrillation (AF) ablation in early heart failure with preserved ejection fraction (HFpEF) is unknown. Our aim was to determine the impact of AF ablation on symptoms and exercise haemodynamic parameters of early HFpEF. METHODS AND RESULTS Symptomatic AF patients referred for index AF ablation with ejection fraction ≥50% underwent baseline quality of life questionnaires, echocardiography, cardiac magnetic resonance imaging, exercise right heart catheterisation (exRHC), and brain natriuretic peptide (BNP) testing. HFpEF was defined by resting pulmonary capillary wedge pressure (PCWP) ≥15 mmHg or peak exercise PCWP ≥25 mmHg. Patients with HFpEF were offered AF ablation and follow-up exRHC ≥6 months post-ablation. Of 54 patients undergoing baseline evaluation, 35 (65%) had HFpEF identified by exRHC. HFpEF patients were older (64 ± 10 vs. 54 ± 13 years, P < 0.01), and more frequently female (54% vs. 16%, P < 0.01), hypertensive (63% vs. 16%, P < 0.001), and suffering persistent AF (66% vs. 11%, P < 0.001), compared to those without HFpEF. Twenty HFpEF patients underwent AF ablation and follow-up exRHC 12 ± 6 months post-ablation. Nine (45%) patients no longer fulfilled exRHC criteria for HFpEF at follow-up. Patients remaining arrhythmia free (n = 9, 45%) showed significant improvements in peak exercise PCWP (29 ± 4 to 23 ± 2 mmHg, P < 0.01) and Minnesota Living with Heart Failure (MLHF) score (55 ± 30 to 22 ± 30, P < 0.01) while the remainder did not (PCWP 31 ± 5 to 30.0 ± 4 mmHg, P = NS; MLHF score 55 ± 23 to 25 ± 20, P = NS). CONCLUSION Heart failure with preserved ejection fraction frequently coexists in patients with symptomatic AF and preserved ejection fraction. Restoration and maintenance of sinus rhythm in patients with comorbid AF and HFpEF improves haemodynamic parameters, BNP and symptoms associated with HFpEF.
Collapse
Affiliation(s)
- Hariharan Sugumar
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,Royal Melbourne Hospital, Melbourne, Australia.,University of Melbourne, Melbourne, Australia
| | - Shane Nanayakkara
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,Monash University, Melbourne, Australia
| | - Donna Vizi
- The Alfred Hospital, Melbourne, Australia
| | - Leah Wright
- Baker Heart & Diabetes Institute, Melbourne, Australia
| | - David Chieng
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,Royal Melbourne Hospital, Melbourne, Australia.,University of Melbourne, Melbourne, Australia
| | - Angeline Leet
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,Monash University, Melbourne, Australia
| | - Justin A Mariani
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,Monash University, Melbourne, Australia
| | - Aleksandr Voskoboinik
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia
| | - Sandeep Prabhu
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia
| | - Andrew J Taylor
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,Monash University, Melbourne, Australia
| | - Jonathan M Kalman
- Royal Melbourne Hospital, Melbourne, Australia.,University of Melbourne, Melbourne, Australia
| | - Peter M Kistler
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,University of Melbourne, Melbourne, Australia
| | - David M Kaye
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,Monash University, Melbourne, Australia
| | - Liang-Han Ling
- Baker Heart & Diabetes Institute, Melbourne, Australia.,The Alfred Hospital, Melbourne, Australia.,University of Melbourne, Melbourne, Australia
| |
Collapse
|
5
|
Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors. Int J Cardiovasc Imaging 2021; 37:1333-1341. [PMID: 33392879 DOI: 10.1007/s10554-020-02122-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Accepted: 11/24/2020] [Indexed: 01/06/2023]
Abstract
The aim of this study was to investigate the association of type 2 diabetes mellitus (T2DM) with the development of new-onset atrial fibrillation (AF) for non-ischemic dilated cardiomyopathy (DCM) patients. We also tested the hypothesis that sodium glucose cotransporter type 2 (SGLT2) inhibitors reduce the risk of development of new-onset AF for non-ischemic DCM patients. We retrospectively studied 210 patients with non-ischemic DCM and sinus rhythm, mean age of 59.0 ± 16.7 years and left ventricular ejection fraction of 31.0 ± 8.2% (all < 45%). T2DM was identified in 60 patients (28.6%), and the remaining 150 patients (71.4%) were classified as non-T2DM patients. New-onset AF occurred in 21 patients (10.0%) over a median follow-up of 6.1 years. Kaplan-Meier curve analysis showed that non-ischemic DCM patients without T2DM experienced fewer occurrences of the development of new-onset AF compared with those with T2DM (log-rank p = 0.0003). Furthermore, global longitudinal strain in patients who showed development of new-onset AF was significantly lower than that in those whose sinus rhythm was preserved (6.4 ± 1.4% vs. 7.7 ± 2.2%, p = 0.01). Of the 60 non-ischemic DCM patients with T2DM, those treated with SGLT2 inhibitors experienced fewer occurrences of the development of new-onset AF than did those not treated with SGLT2 inhibitors (log-rank p = 0.040). T2DM is associated with the development of new-onset AF in non-ischemic DCM patients, and treatment with SGLT2 inhibitors can significantly reduce the development of new-onset AF. Our findings may thus offer a new insight into the management of non-ischemic DCM patients with T2DM.
Collapse
|